irblog.prnewswire.com

BIOTRONIK Announces FDA Approval of MR Conditional Cardiac Resynchronization Defibrillators

More than five million Americans suffer from heart failure (HF). The condition occurs when the heart isn't able to pump enough blood and oxygen to the rest of the body. Patients, often elderly and ...
irblog.prnewswire.com

BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System

LAKE OSWEGO, Ore., July 3, 2017 /PRNewswire/ -- BIOTRONIK today announced the results of the BIOFLEX-I clinical study and availability of Pulsar ®-18 for the treatment of patients with peripheral ...
Yahoo Finance

BIOTRONIK Expands Cardiac Rhythm Care by Launching World's First CRT-D Systems Approved for Conduction System Pacing

BERLIN, Feb. 12, 2026 /PRNewswire/ -- BIOTRONIK today announced the launch of the new Acticor Sky and Rivacor Sky device family featuring the world's first CE-approved left bundle branch area pacing ...
Yahoo Finance

BIOTRONIK Neuro Launches Embrace One® Proactive Intelligence, a Proprietary AI Capability that Identifies Emerging Support Needs in SCS Patients

MIAMI, July 20, 2026 /PRNewswire/ -- BIOTRONIK Neuro today announced the launch of Embrace One® Proactive Intelligence, a proprietary AI capability that advances proactive care for patients implanted ...
Business Wire

BIOTRONIK Launches First 20 mm–200 mm Stents on 4 F Platform for Treatment of SFA and BTK Disease

BUELACH, Switzerland--(BUSINESS WIRE)--BIOTRONIK AG, a leading manufacturer of vascular interventional devices, announced the introduction of a line extension to its popular 4 F compatible, ...
TCTMD

Biotronik launches 2 new studies

Biotronik announced 2 new studies last week that are slated to examine the company’s CRT-D device and BioMonitor implanted cardiac monitor. A 277-patient BioContinue clinical trial will examine the ...
MD&M East

Long-Term Data for Biotronik’s Orsiro DES Holds Up

Biotronik is solidifying the Orsiro Drug-Eluting Stents position in the market with favorable five-year data. The Lake Oswego, OR-based company presented data from the BIOFLOW-V trial at the 2022 CRT ...
MD&M East

Biotronik Has a New DES Added to its Repertoire

FDA has just signed off on Biotronik’s Orsiro drug-eluting stent (System). The Lake Oswego, OR-based company claims the stent is the first and ultrathin DES to outperform Abbott Laboratories’, Xience ...
Medscape

FDA approves Biotronik Home Monitoring System pacemaker

Lake Oswego, OR - The first wireless communication system for remote monitoring of implantable pacemakers won FDA approval yesterday. The Biotronik Home Monitoring System allows a Biotronik pacemaker ...
Business Wire

BIOTRONIK Receives FDA Approval for Expansion of the Premium Evia Pacemaker Portfolio

LAKE OSWEGO, Ore. & BERLIN--(BUSINESS WIRE)--BIOTRONIK, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies, today announced FDA approval of ...
TCTMD

BIOTRONIK Announces FDA Approval of MR Conditional Cardiac Resynchronization Defibrillators

LAKE OSWEGO, Ore., BIOTRONIK, a leader in cardio- and endovascular medical technology, today announced Food and Drug Administration (FDA) approval of Iperia ProMRI HF-T, a cardiac resynchronization ...